VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was featured in an Equity Research Company Update by Maxim Group LLC. The report, titled “Benzo-Benefits Without the Benzo-Baggage – The Case for PH94B Builds,” highlights potential benefits of VistaGen’s PH94B drug candidate, a nasal spray designed for treatment of adults with social anxiety disorder, as compared to treatment with benzodiazepines. The report reads, “Benzodiazepines (benzos) have been available to treat anxiety since the 1960s, and include well-known products such as Xanax, Ativan, and Klonopin. These drug compounds work by binding to the receptors located on GABA (gamma-aminobutyric acid), the main inhibitory neurotransmitter in the brain. Although benzos produce anxiolytic effects, they are highly addictive and come with a host of side effects (sedation, impaired cognition, etc). Essentially, anywhere there is GABA, a benzo will have an impact and thats an issue. PH94B is a neuroactive steroid called a pherine, which also activates GABA neurotransmission, but only in the central amygdala and not throughout the entire brain and central nervous system. Through its nasal spray formulation, a small amount of PH94B is delivered locally to cells in the nasal passages to activate chemosensory neurons that trigger neural circuits in the brain which suppress fear and anxiety. The drug itself never enters the brain, a key differentiator.”
To view the full report, visit https://ibn.fm/eOwEf
About VistaGen Therapeutics
VistaGen is a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other CNS disorders where the current standard of care is inadequate, resulting in high unmet need. Each of VistaGens three drug candidates has a differentiated mechanism of action, an exceptional safety profile in all studies to date, and therapeutic potential in multiple CNS markets. For more information, please visit www.VistaGen.com.
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text STOCKS to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork
